(HealthDay News) — For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published online in Diabetes, Obesity and Metabolism.

Thomas Nyström, MD, from Karolinska Institutet in Stockholm, and colleagues compared use of novel oral GLDs (either dipeptidyl-peptidase-4 inhibitors [DPP-4i] or sodium glucose cotransporter-2 inhibitors) with insulin treatment in a propensity score matched analysis involving 21,758 patients matched in a 1:1 ratio.

The researchers observed reductions in the risk of all-cause mortality, CVD, and hypoglycemia in the novel GLD group vs the insulin group (hazard ratios [HRs], 0.56 [95% confidence interval (CI), 0.49 to 0.64], 0.85 [95% CI, 0.73 to 0.99], and 0.26 [95% CI, 0.12 to 0.57], respectively). Dapagliflozin correlated with lower risks of all-cause mortality and CVD (HRs, 0.44 [95% CI, 0.28 to 0.70] and 0.51 [95% CI, 0.30 to 0.86], respectively), while DPP-4i correlated with reduced risk of all-cause mortality (HR, 0.59 [95% CI, 0.51 to 0.67]) but not CVD (HR, 0.87 [95% CI, 0.75 to 1.01]).

“Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality,” the authors write.


Continue Reading

Several authors disclosed financial ties to the pharmaceutical industry.

Related Articles

Reference

  1. Nyström T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients. Diabetes Obes Metab. 24 January 2017. doi: 10.1111/dom.12889.